Search research articles
Contact Us
Filters
Showing results (51-60 of 67) with videos related to
Page
of 7
Sort By:
ESMO Open
|
April 25, 2022
Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]
D König, S Schär, D Vuong, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial
S Peters, E Felip, U Dafni, et al.
ESMO Open
|
April 10, 2022
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
D König, S Schär, D Vuong, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
November 14, 2022
Correction to: Stereotactic radiosurgery and radiotherapy for resected brain metastases: current pattern of care in the Radiosurgery and Stereotactic Radiotherapy Working Group of the German Association for Radiation Oncology (DEGRO)
S Rogers, B Baumert, O Blanck, et al.
Clinical and Translational Radiation Oncology
|
April 8, 2024
Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer - Acute toxicity and patient-reported outcomes in the prospective, multicenter <i>SMILE</i> phase II trial
C A Fink, J Ristau, C Buchele, et al.
ESMO Open
|
July 13, 2023
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14
D König, S Savic Prince, S Hayoz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)
S Peters, U Dafni, M Boyer, et al.
BMC Cancer
|
May 14, 2020
PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial
A De Bruycker, A Spiessens, P Dirix, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 8, 2018
Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy
R J Klement, J Hoerner-Rieber, S Adebahr, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
July 1, 2021
Improving interinstitutional and intertechnology consistency of pulmonary SBRT by dose prescription to the mean internal target volume dose
L Wilke, C Moustakis, O Blanck, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 67) with videos related to
Sort By:
Page
of 7
ESMO Open
|
April 25, 2022
Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]
D König, S Schär, D Vuong, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial
S Peters, E Felip, U Dafni, et al.
ESMO Open
|
April 10, 2022
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
D König, S Schär, D Vuong, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
November 14, 2022
Correction to: Stereotactic radiosurgery and radiotherapy for resected brain metastases: current pattern of care in the Radiosurgery and Stereotactic Radiotherapy Working Group of the German Association for Radiation Oncology (DEGRO)
S Rogers, B Baumert, O Blanck, et al.
Clinical and Translational Radiation Oncology
|
April 8, 2024
Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer - Acute toxicity and patient-reported outcomes in the prospective, multicenter <i>SMILE</i> phase II trial
C A Fink, J Ristau, C Buchele, et al.
ESMO Open
|
July 13, 2023
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14
D König, S Savic Prince, S Hayoz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)
S Peters, U Dafni, M Boyer, et al.
BMC Cancer
|
May 14, 2020
PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial
A De Bruycker, A Spiessens, P Dirix, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 8, 2018
Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy
R J Klement, J Hoerner-Rieber, S Adebahr, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
July 1, 2021
Improving interinstitutional and intertechnology consistency of pulmonary SBRT by dose prescription to the mean internal target volume dose
L Wilke, C Moustakis, O Blanck, et al.
Page
of 7